Search for: "Sanofi S A"
Results 21 - 40
of 933
Sort by Relevance
|
Sort by Date
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
6 Mar 2024, 10:15 am
Sanofi Pasteur Inc. affirming lower rulings by the Patent Trial and Appeal Board (PTAB) that invalidated Pfizer’s patent claims and denied motions to amend (MTA). [read post]
6 Mar 2024, 10:15 am
Sanofi Pasteur Inc. affirming lower rulings by the Patent Trial and Appeal Board (PTAB) that invalidated Pfizer’s patent claims and denied motions to amend (MTA). [read post]
5 Mar 2024, 10:55 am
All notices of correction are posted and maintained on HRSA’s ceiling price website. [read post]
5 Mar 2024, 10:23 am
Sanofi Opinion. [read post]
23 Jan 2024, 9:01 pm
Allianz Allianz Global’s $145 million payout benefits shareholders of collapsed mutual funds that Allianz managed. [read post]
21 Jan 2024, 9:01 pm
In Illumina/Grail, the Fifth Circuit reviewed the Commission’s reversal of the ALJ’s dismissal of the complaint. [read post]
18 Jan 2024, 5:14 pm
Sanofi et al. [read post]
11 Jan 2024, 9:31 pm
Sanofi decision: What’s Next for Biotechnology Claims? [read post]
11 Jan 2024, 12:59 pm
Sanofi, 143 S. [read post]
9 Jan 2024, 3:30 pm
Sanofi. [read post]
9 Jan 2024, 3:30 pm
Sanofi. [read post]
31 Dec 2023, 4:29 pm
Sanofi In this case, the Supreme Court considered the validity of certain patents on antibodies used to lower cholesterol under the Patent Act’s enablement requirement (35 U.S.C. 112(a)). [read post]
29 Dec 2023, 4:00 am
Sanofi U.S. [read post]
27 Dec 2023, 5:51 am
Ultimately it was held that Sanofi’s central division revocation action won the day, having been filed by hand some 19 minutes before Amgen’s infringement action arrived at the Munich local division. [read post]
22 Dec 2023, 5:29 am
It is also hard not to wonder about the EPO's current preference for the term "credibility" in place of plausibility. [read post]
20 Dec 2023, 5:00 am
The pro-Sanofi briefs, in addition to weighing in on the facts of the case (e.g., how many antibodies were in Amgen’s genus, how thorough was Amgen’s disclosure), ar [read post]
15 Dec 2023, 1:16 pm
The post Sanofi Abandons Deal For Rare Disease Drug Amid FTC’s Monopoly Concerns appeared first on Above the Law. [read post]
15 Dec 2023, 12:48 pm
This week in Other Barks & Bites: a group of authors filed a trimmed-down lawsuit against Meta accusing the company of infringing copyright to train generative AI models; the FTC authorizes a lawsuit against Sanofi accusing a potential acquisition of being a move to monopolize Pompe disease drug development; and Chinese courts publish rulings to combat malicious trademarks. [read post]
15 Dec 2023, 12:48 pm
This week in Other Barks & Bites: a group of authors filed a trimmed-down lawsuit against Meta accusing the company of infringing copyright to train generative AI models; the FTC authorizes a lawsuit against Sanofi accusing a potential acquisition of being a move to monopolize Pompe disease drug development; and Chinese courts publish rulings to combat malicious trademarks. [read post]
